|
Jan 6
|
Patient Enrolment Completed for INSIGHT-003
|
|
Oct 10
|
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Jun 25
|
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Feb 5
|
10 Best Australian Stocks To Buy
|
|
Jan 4
|
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
|
|
Dec 21
|
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Dec 7
|
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
|
|
Nov 27
|
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
|
|
Nov 9
|
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
|
|
Sep 25
|
Immutep Limited (ASX:IMM): Is Breakeven Near?
|